Your browser doesn't support javascript.
Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?
Mornese Pinna, Simone; Lupia, Tommaso; Scabini, Silvia; Vita, Davide; De Benedetto, Ilaria; Gaviraghi, Alberto; Colasanto, Irene; Varese, Alessandra; Cattel, Francesco; De Rosa, Francesco Giuseppe; Corcione, Silvia.
  • Mornese Pinna S; Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy.
  • Lupia T; Unit of Infectious Diseases, Cardinal Massaia Hospital, Asti, Italy. Electronic address: tommaso.lupia89@gmail.com.
  • Scabini S; Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy.
  • Vita D; Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy.
  • De Benedetto I; Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy.
  • Gaviraghi A; Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy.
  • Colasanto I; S.C. Farmacia Ospedaliera -A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy.
  • Varese A; S.C. Farmacia Ospedaliera -A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy.
  • Cattel F; S.C. Farmacia Ospedaliera -A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy.
  • De Rosa FG; Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy.
  • Corcione S; Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy; Tufts University School of Medicine, Boston, MA, USA.
Int Immunopharmacol ; 101(Pt A): 108200, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1440133
ABSTRACT
The world is facing up the most considerable vaccination effort in history to end the Coronavirus disease 2019 (COVID-19) pandemic. Several monoclonal antibodies (mAbs) direct against the Receptor binding domain of the S protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) received an Emergency Use Authorization for outpatient management of mild to moderate manifestation from COVID-19. MAbs could prevent the transmission SARS-CoV-2 infection and protect individuals from progression to severe disease. Under the pressure of different treatment strategies, SARS-CoV-2 has been demonstrated to select for different sets of mutations named "variants" that could impair the effectiveness of mAbs by modifying target epitopes. We provide an overview of both completed and unpublished, or ongoing clinical trials of mAbs used and review state of art in order to describe clinical options, possible indications, and the place in therapy for these agents in the treatment of COVID-19 with a particular focus on anti-spike agents. Then, we reassume the current evidence on mutations of the SARS-CoV-2 that might confer resistance to neutralization by multiple mAbs.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 / Antibodies, Monoclonal / Antibodies, Viral Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Int Immunopharmacol Journal subject: Allergy and Immunology / Pharmacology Year: 2021 Document Type: Article Affiliation country: J.intimp.2021.108200

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 / Antibodies, Monoclonal / Antibodies, Viral Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Int Immunopharmacol Journal subject: Allergy and Immunology / Pharmacology Year: 2021 Document Type: Article Affiliation country: J.intimp.2021.108200